Study Summary
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Protocol: 23-1025 / IRB23-1025
Investigator: Jeremy G. Price, MD, PhD
Disease(s): Cervix
Location(s): Fox Chase Cancer Center at Cottman Ave
Inclusion/Exclusion Criteria:
Contact Us
About This Trial:
For more information about this and other studies and to inquire about eligibility, please call 215-214-1515 or fill out this form.
- Female patients over the age of 18 years old who must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2018 clinical stages IB2-IVA, without involved paraaortic lymph nodes
- Patients who have involved pelvic lymph nodes, the upper border of the CTV nodal volume may not extend above the confluence of the common iliac arteries with the aorta (pelvic nodal status to be confirmed by PET/CT, CT scan, MR scan, fine needle biopsy)
- Patients must not have had a hysterectomy
- Patients must be planning to undergo concurrent pelvic radiation and chemotherapy
- Patients must have normal organ and marrow functions
- Patients may not have any prior radiation therapy to the pelvis or abdominal cavity, no staging pelvic or paraaortic lymphadenectomy, no prior systemic anticancer therapy within three years
For more information about this and other studies and to inquire about eligibility, please call 215-214-1515.